Getting the dose right in dermatological therapy

Dermatologic, Cosmeceutic, and Cosmetic Development: Therapeutic and Novel Approaches

Volumn , Issue , 2007, Pages 197-214

  Davis, Adrian F ^a  

^a Limeway Consultancy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056936156     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (98)

1. Maibach HI. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 1976;152 Suppl 1:11-25.
2. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115(4):475-484.
3. Sultzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952;19(2):101-102.
4. Keczkes K, Frain-Bell W, Honeyman AL, et al. The effect of adrenal function of treatment of eczema and psoriasis with triamcinolone acetonide. Br J Dermatol 1967;79(8):475-486.
5. Marples RR, Kligman AM, Methods for evaluating topical antibacterial agents on human skin. Antimicrob Agents Chemother 1974; 5:323-379.
6. Langford JH, Benrimoj SI. Clinical rationale for topical antimicrobial preparations. J Antimicrob Chemother 1996;37(3):399-402.
7. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141(2):264-73.
8. Meingassner JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137(4):568-576.
9. Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. Br J Dermatol 2002;146(2):342.
10. Wach F, Bosserhoff A, Kurzidym U, et al. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998;11(1):43-51.
11. Korting HC, Unholzer A, Schafer-Korting M, et al. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002;15(2):85-91.
12. Koivukangas V, Karvonen J, Risteli J, et al. Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995;132(1):66-68.
13. Bershad S. Developments in topical retinoid therapy for acne. Sem Cutaneous Med Surg 2001;20:154-161.
14. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol 2000;43:51-54.
15. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967;48(2):181-183.
16. Feldmann RJ, Maibach HI. Penetration of 14C hydrocortisone through normal skin: the effect of stripping and occlusion. Arch Dermatol 1965;91:661-666.
17. Martin EG, Sanchez RM, Herrera AE, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006;5(4):334-336.
18. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141(1):103-107.
19. Hadgraft J, Whitefield M, Rosher PH. Skin penetration of topical formulations of ibuprofen 5%: an in vitro comparative study. Skin Pharmacol Appl Skin Physiol 2003;16(3):137-142.
20. Trottet L, Owen H, Holme P, et al. Are all aciclovir cream formulations bioequivalent? Int J Pharm 2005;304(1-2):63-71.
21. Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997;9(3-4):227-364.
22. Hoppmann J, Baumer W, Galetzka C, et al. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol 2005;57(12):1609-1617.
23. Muller M, Rastelli C, Ferri P, et al. Transdermal penetration of diclofenac after multiple epicutaneous administration. J Rheumatol 1998;25(9):1833-1836.
24. Dehghanyar P, Mayer BX, Namiranian K, et al. Topical skin penetration of diclofenac after single- and multiple-dose application. Int J Clin Pharmacol Ther 2004;42(7):353-359.
25. Churchill L et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996; 4:135.
26. Cromlish W, Kennedy BP. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assay. Biochem Pharmacol 1996;52:1777-1785.
27. Salde L, Lassus A. Systemic side-effects of three topical steroids in diseased skin. Curr Med Res Opin 1983;8(7):475-480.
28. Berth-Jones J, Bourke JF, Iqbal SJ, et al. Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 1993;129(4):411-414.
29. Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994;235(3):281-282.
30. Chen C, Jensen BK, Mistry G, et al. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol 1997;37(4):279-284.
31. Baumer W, Hoppmann J, Rundfeldt C, et al. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6(1):17-26.
32. Zell-Kanter M, Toerne TS, Spiegel K, et al. Doxepin toxicity in a child following topical administration. Ann Pharmacother 2000;34(3):328-329.
33. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107(1):51-56.
34. Heise R, Mey J, Neis MM, et al. Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin models. J Invest Dermatol 2006;126(11):2473-2480.
35. Schuster I, Egger H, Bikle D, et al. Selective inhibition of vitamin D hydroxylases in human keratinocytes. Steroids 2001;66(3-5):409-422.
36. Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989;125(11):1509-1511.
37. Barry BW, Fyrand O, Woodford R, et al. Control of the bioavailability of a topical steroid; comparison of desonide creams 0.05% and 0.1% by vasoconstrictor studies and clinical trials. Clin Exp Dermatol 1987;12(6):406-409.
38. Gibson JR, Kirsch J, Darley CR, et al. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations. Br J Dermatol 1983;109 Suppl 25:114-116.
39. Kirsch J, Gibson JR, Darley CR, et al. A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasoconstrictor assay. Dermatologica 1983;167(3):138-141.
40. Kirsch JM, Gibson JR, Darley C, et al. Extemporaneous dilutions of proprietary topical corticosteroid preparations. Dermatologica 1982;165(1):71-72.
41. Martin GP. The effect of dose under a hydrocolloid patch on the human bioavailability of a topical cortisosteroid. J Pharm Pharmacol 1989;41:129.
42. Ostrenga J, Steinmetz C, Poulsen B, et al. Significance of vehicle composition. II. Prediction of optimal vehicle composition. J Pharm Sci 1971;60(8):1180-1183.
43. Ostrenga J, Steinmetz C, Poulsen B. Significance of vehicle composition. I. Relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 1971;60(8):1175-1179.
44. Poulsen BJ. Diffusion of drugs from topical vehicles: an analysis of vehicle effects. Adv Biol Skin 1972;12:495-509.
45. Lippold BC, Schneemann H. The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution- and suspension-type ointments. Int J Pharmaceut 1984;22:31-43.
46. Malzfeldt E, Lehmann P, Goerz G, et al. Influence of drug solubility in the vehicle on clinical efficacy of ointments. Arch Dermatol Res 1989;281(3):193-197.
47. Bennett SL, Barry BW, Woodford R. Optimization of bioavailability of topical steroids:non-occluded penetration enhancers under thermodynamic control. J Pharm Pharmacol 1985;37(5):298-304.
48. Woodford R, Barry BW. Optimization of bioavailability of topical steroids: thermodynamic control. J Invest Dermatol 1982;79(6):388-391.
49. Hadgraft J, Hadgraft JW, Sarkany I. Proceedings: the effect of thermodynamic activity on the percutaneous absorption of methyl nicotinate from water glycerol mixtures. J Pharm Pharmacol 1973;25:Suppl:122-123.
50. Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000;198(2):229-238.
51. Leichtnam ML, Rolland H, Wuthrich P, et al. Enhancement of transdermal testosterone delivery by supersaturation. J Pharm Sci 2006;95(11):2373-2379.
52. Moser K, Kriwet K, Froehlich C, et al. Permeation enhancement of a highly lipophilic drug using supersaturated systems. J Pharm Sci 2001;90(5):607-616.
53. Bach M, Lippold BC. Percutaneous penetration enhancement and its quantification. Eur J Pharm Biopharm 1998 Jul;46(1):1-13.
54. Spruance SL, McKeough M, Sugibayashi K, et al. Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs. Antimicrobial 1984; 26:819-823.
55. Spruance SL, McKeough MB, Cardinal JR. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection. Antimicrobial 1984; 25:10-15.
56. Imanidis G, Song WQ, Lee PH, et al. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice. Pharm Res 1994;11:1035-1041.
57. Lee PH, Su MH, Kern ER, et al. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice. Pharm Res 1992;9:970-989.
58. Mehta SC, Afouna MI, Ghanem AH, et al. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug. J Pharm Sci 1997;86:797-801.
59. Patel PJ, Ghanem AH, Higuchi WI, et al. Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV- 1 infections in hairless mice: an evaluation of the predictive value of the C* concept. Antiviral Res 1996;29:279-286.
60. Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efficacy. J Pharm Pharmacol 1997;49(9):866-872.
61. Wenkers BP, Lippold BC. Prediction of the efficacy of cutaneously applied nonsteroidal anti-inflammatory drugs from a lipophilic vehicle. Arzneimittelforsch 2000;50(3):275-280.
62. Cordero JA, Camacho M, Obach R, et al. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001;51(2):135-142.
63. Cordero JA, Alarcon L, Escribano E, et al. A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci 1997;86(4):503-508.
64. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005;8;6:44.
65. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31(10):2002-2012.
66. Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33(3):567-573.
67. Esparza F, Cobian C, Jimenez JF, et al. Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries. Br J Sports Med 2007;41(3):134-139.
68. Mazieres B, Rouanet S, Guillon Y, et al. Topical ketoprofen patch in the treatment of tendinitis: a randomized, double blind, placebo controlled study. J Rheumatol 2005;32(8):1563-1570.
69. Guy RH, Potts RO. Structure-permeability relationships in percutaneous penetration. J Pharm Sci 1992;81(6):603-604.
70. Potts RO, Guy RH. Predicting skin permeability. Pharm Res 1992;9(5):663-669.
71. Trottet T. Topical pharmacokinetics for a rational and effective topical drug development process. PhD thesis, 2005, University of Wales, Cardiff.
72. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig 2006;26(5):235-246.
73. Frohna JG. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. J Pediatr 2005;147(1):126.
74. Bunse T, Schulze HJ, Mahrle G. Topical administration of cyclosporin in psoriasis vulgaris. Z Hautkr 1990;65(6):538, 541-542.
75. Cole GW, Shimomaye S, Goodman M. The effect of topical cyclosporin A on the elicitation phase of allergic contact dermatitis. Contact Dermatitis 1988;19(2):129-132.
76. Ault JM, Riley CM, Meltzer NM, et al. Dermal microdialysis sampling in vivo. Pharm Res 1994;11(11):1631-1639.
77. Scott A, Kalz F. The penetration and distribution of C14-hydrocortisone in human skin after its topical application. J Invest Dermatol 1956;26(2):149-158.
78. Witten VH, Shapiro AJ, Silber RH. Attempts to demonstrate absorption of hydrocortisone by new chemical test following induction into human skin. Proc Soc Exp Biol Med 1955;88(3):419-421.
79. Malkinson FD, Kirschenbaum MB. Percutaneous absorption of C14-labelled triamcinolone acetonide. Arch Dermatol 1963;88:427-439.
80. Malkinson FD, Ferguson EH, Wang MC, Percutaneous absorption of cortisone C14 through normal human skin. J Invest Dermatol. 1957;28(3):211-216.
81. Anderson CD. Cutaneous microdialysis: is it worth the sweat? J Invest Dermatol 2006;126(6):1207-1209.
82. Ault JM, Lunte CE, Meltzer NM, et al. Microdialysis sampling for the investigation of dermal drug transport. Pharm Res 1992;9(10):1256-1261.
83. Gottlob A, Abels C, Landthaler M, et al. Cutaneous microdialysis. Use in dermatology. Hautarzt 2002;53(3):174-178.
84. Klimowicz A, Farfal S, Bielecka-Grzela S. Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: acyclovir vs. salicylic acid. J Clin Pharm Ther 2007;32(2):143-148.
85. Kreilgaard M. Assessment of cutaneous drug delivery using microdialysis. Adv Drug Deliv Rev 2002;54 Suppl 1:S99-S121.
86. Kreilgaard M. Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. Pharm Res 2001;18(3):367-373.
87. Morgan CJ, Renwick AG, Friedmann PS. The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. Br J Dermatol 2003;148(3):434-443.
88. Alberti I, Kalia YN, Naik A, et al. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res 2001;18(10):1472-1475.
89. Herkenne C, Naik A, Kalia YN, et al. Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest Dermatol 2007;127(4):887-894.
90. Herkenne C, Naik A, Kalia YN, et al. Ibuprofen transport into and through skin from topical formulations: in vitro-in vivo comparison. J Invest Dermatol 2007;127(1):135-142.
91. Reddy MB, Stinchcomb AL, Guy RH, et al. Determining dermal absorption parameters in vivo from tape strip data. Pharm Res 2002;19(3):292-298.
92. Barry BW, Woodford R. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations. Br J Dermatol 1976;95(4):423-425.
93. Cornell R. Fluticasone propionate ointment 0.005%: its lack of suppression of the HPA axis when used for the treatment of psoriasis or eczema. Abstract presented at the Annual AAD meeting, Washington, 1996, 10-15 ed.
94. Tan MH, Meador SL, SingerG, et al. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol. 2002;41(11):804-809.
95. Davis AF. Novel formulations for improved therapy. PhD thesis 1995. University of Wales, Cardiff.
96. Marks R, Dykes PJ, Gordon J, et al. Percutaneous penetration from a low-dose supersaturated hydrocortisone acetate formulation. Society of Investigative Dermatology Annual Meeting, Sheffield, September 1992.
97. Duell EA, Astrom A, Griffiths CE, et al. Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J Clin Invest 1992;90(4):1269-1274.
98. Shah VP. Transdermal drug delivery system regulatory issues. In: Guy RH, Hadgraft, J eds. Transdermal Drug Delivery, Drugs and the Pharmaceutical Sciences Series 2003, volume 123, Chapter 11. Basal, New York: Marcel Dekker, Inc., pp 361-367.